AbCellera Biologics (ABCL) Long-Term Investments (2020 - 2026)

AbCellera Biologics has reported Long-Term Investments for 7 years, with the latest figure at $65.3 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 19.93% year-over-year to $65.3 million; the trailing twelve-month figure through Mar 2026 stood at $65.3 million (down 19.93% YoY), and the FY2025 full-year result was $62.6 million, down 23.96% from the prior year.
• Long-Term Investments for Q1 2026 stood at $65.3 million, up from $62.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $93.3 million in Q3 2025, with the low at $57.6 million in Q1 2023.
• Historically, Long-Term Investments has averaged $71.5 million across 5 years, with a median of $66.7 million in 2022.
• Annual changes were most pronounced in 2022 — Long-Term Investments jumped 82.94% — and 2025, when it dropped 23.96%.
• AbCellera Biologics' Long-Term Investments stood at $72.5 million in 2022, then dropped by 9.08% to $65.9 million in 2023, then grew by 24.81% to $82.3 million in 2024, then slipped by 23.96% to $62.6 million in 2025, then grew by 4.36% to $65.3 million in 2026.
• The last three Long-Term Investments figures came in at $65.3 million (Q1 2026), $62.6 million (Q4 2025), and $93.3 million (Q3 2025), per Business Quant data.